In a report published Monday, Piper Jaffray & Co. reiterated its Overweight rating on Rigel Pharmaceuticals RIGL, but lowered its price target from $16.00 to $14.00.
Piper Jaffray noted, “We are reiterating our Overweight rating ahead of data from all three fostamatinib Phase III trials in early 2013. We believe the OSKIRA-4 Phase II trial (4Q12) could provide investors with an early look at fostamatinib's efficacy and safety prior to the Phase III readouts expected in January 2013. We believe the OSKIRA-4 trial could address lingering concerns related to blood pressure elevations and market positioning of fostamatinib; ultimately reducing risk associated with the Phase III data release. We continue to expect fostamatinib to generate $1-2bn in peak sales in RA alone, with Rigel collecting a 25-30% royalty at no cost.”
Rigel Pharmaceuticals closed on Friday at $9.25.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in